European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F22%3A43923561" target="_blank" >RIV/00216208:11120/22:43923561 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1016/j.ejca.2022.03.008" target="_blank" >https://doi.org/10.1016/j.ejca.2022.03.008</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejca.2022.03.008" target="_blank" >10.1016/j.ejca.2022.03.008</a>

Result language

angličtina

Original language name

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

Original language description

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts&apos; experience. The diagnosis of melanoma can be made clinically and shall always be confirmed with dermatoscopy. If a melanoma is suspected, a histopathological examination is always required. Sequential digital dermatoscopy and full body photography can be used in high-risk patients to improve the detection of early melanoma. Where available, confocal reflectance microscopy can also improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the American Joint Committee on Cancer classification. Thin melanomas up to 0.8 mm tumor thickness do not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC onwards whole-body examinations with computed tomography (CT) or positron emission tomography CT (PET-CT) in combination with brain magnetic resonance imaging are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to define the frequency and extent of examinations. A stage-based follow-up scheme is proposed which, according to the experience of the guideline group, covers the optimal requirements, but further studies may be considered. This guideline is valid until the end of 2024.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Cancer

ISSN

0959-8049

e-ISSN

1879-0852

Volume of the periodical

170

Issue of the periodical within the volume

July

Country of publishing house

GB - UNITED KINGDOM

Number of pages

20

Pages from-to

236-255

UT code for WoS article

000833527200003

EID of the result in the Scopus database

2-s2.0-85130412196